Chemoradiation combined with immunotherapy significantly boosts survival in patients with resected extrahepatic cholangiocarcinoma and gallbladder cancer.
Camrelizumab plus concurrent capecitabine and radiotherapy improved overall survival and recurrence-free survival in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer .Patients with EHC and gallbladder cancer have a high recurrence rate and poor survival after surgery.
Existing adjuvant therapies provide limited benefit, underscoring the need for novel treatment combinations. This multicenter, randomized clinical trial investigated the safety and efficacy of chemoradiation with anti-PD-1 immunotherapy in these patients. A total of 93 patients with histologically confirmed EHC or gallbladder cancer who underwent curative resection with stage pT2-4 or N1M0 disease were randomly assigned to either the combination treatment group or the observation group .oral capecitabine twice daily with radiotherapy . The primary endpoint was OS, and secondary endpoints were recurrence-free survival and adverse events . The median follow-up duration was 36 months.The median recurrence-free survival was longer in the combination treatment group than in the observation group , radiation-associated dermatitis , nausea , and hand-foot syndrome in the combination group and anemia , fatigue , and neutropenia in the observation group. Subgroup analyses suggested patients with EHC vs gallbladder cancer and those with an Eastern Cooperative Oncology Group score of 0 and tumors ≤ 5 cm were more likely to benefit from the combination treatment.“We congratulate the authors for conducting and reporting an important clinical trial that moves the field forward. Considering the current level of evidence used to guide patient management after resection, we suspect this regimen may be adopted into practice even prior to the conduct of a phase 3 trial,” Edgar Ben-Josef, MD, University of Pennsylvania, Philadelphia, wrote, in. “However, we would caution that this study should be viewed not as an ending but as a building block toward studies that demonstrate an even greater level of confidence more effective adjuvant regimens for patients with biliary cancers.This study was only conducted on Chinese patients, limiting generalizability to Western populations. Although the study met the predefined 2-year follow-up for all patients, both groups showed better-than-expected OS rates, resulting in fewer endpoint events than anticipated. Additionally, the open-label design and the combination of multiple treatments might have confounded efficacy assessment for each treatment component.This study received project grants from the National Natural Science Foundation of China and the Science and Technology Program of Guangzhou. The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our
Noncolorectal GI Cancer Hepatocellular Carcinoma Liver Cancer HCC Hepatocellular Cancer Cancer Of The Liver Liver Carcinoma Carcinoma Of The Liver Hepatocellular Carcinoma (HCC) Biologic Therapy Biologics Gallbladder Cancer Gallbladder Carcinoma Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Cholangiocarcinoma Gallbladder Immunotherapy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Do You Treat Stage IIB Melanoma?Dr Teresa Amaral poses a treatment question for a hypothetical patient after sharing information on biomarkers and adjuvant therapy in previous discussions.
Read more »
Opinion: Newsom’s return-to-office quest ignores overwhelming evidenceWorking from home boosts productivity, reduces freeway congestion, lowers office costs and enhances morale, data shows.
Read more »
Comparing Adjuvant Immunotherapy vs Targeted Therapy in Stage III BRAF-Mutant MelanomaDr Teresa Amaral discusses real-world data comparing adjuvant immunotherapy vs targeted therapy in stage III BRAF-mutant melanoma.
Read more »
25x speed breakthrough in solid-state battery manufacturing achieved by US firmQuantumScape unveils 'Cobra,' a new manufacturing process that boosts solid-state battery production speed by 25x.
Read more »
Real-World Data: Adjuvant Therapy for BRAF-Mutated MelanomaDr Teresa Amaral finishes the discussion about real-world data on adjuvant therapy in patients with BRAF-mutated melanoma.
Read more »
Menopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers SayGood news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new study says.
Read more »